How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research

被引:2
|
作者
Rivera, Francisco J. Sanchez [1 ,2 ]
Dow, Lukas E. [3 ,4 ,5 ]
机构
[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA
[2] MIT, Dept Biol, Cambridge, MA 02142 USA
[3] Sandra & Edward Meyer Canc Ctr, Weill Cornell Med, New York, NY 10065 USA
[4] Dept Biochem, Weill Cornell Med, New York, NY 10065 USA
[5] Dept Med, Weill Cornell Med, New York, NY 10065 USA
来源
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2024年 / 14卷 / 05期
关键词
ONE-STEP GENERATION; TUMOR-SUPPRESSOR; CHROMOSOMAL TRANSLOCATIONS; MOUSE GENOME; LUNG-CANCER; LENTIVIRAL VECTOR; COLORECTAL-CANCER; CAS SYSTEMS; HUMAN-CELLS; OFF-TARGET;
D O I
10.1101/cshperspect.a041384
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cancers arise through acquisition of mutations in genes that regulate core biological processes like cell proliferation and cell death. Decades of cancer research have led to the identification of genes and mutations causally involved in disease development and evolution, yet defining their precise function across different cancer types and how they influence therapy responses has been challenging. Mouse models have helped define the in vivo function of cancer-associated alterations, and genome-editing approaches using CRISPR have dramatically accelerated the pace at which these models are developed and studied. Here, we highlight how CRISPR technologies have impacted the development and use of mouse models for cancer research and discuss the many ways in which these rapidly evolving platforms will continue to transform our understanding of this disease.
引用
收藏
页数:30
相关论文
共 50 条
  • [41] Genetically engineered mouse models in oncology research and cancer medicine
    Kersten, Kelly
    de Visser, Karin E.
    van Miltenburg, Martine H.
    Jonkers, Jos
    EMBO MOLECULAR MEDICINE, 2017, 9 (02) : 137 - 153
  • [42] MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy
    Cao, Zhe
    Qiu, Jiangdong
    Yang, Gang
    Liu, Yueze
    Luo, Wenhao
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    CANCER BIOLOGY & MEDICINE, 2020, 17 (03) : 569 - 582
  • [43] Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
    Le, Tri
    Gerber, David E.
    CANCERS, 2019, 11 (03)
  • [44] Organoid: Next-Generation Modeling of Cancer Research and Drug Development
    Liu, Jungang
    Huang, Xiaoliang
    Huang, Lihaoyun
    Huang, Jinlian
    Liang, Dingyu
    Liao, Lixian
    Deng, Yuqing
    Zhang, Lihua
    Zhang, Beibei
    Tang, Weizhong
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [45] Rapid generation of novel models of RAG1 deficiency by CRISPR/Cas9-induced mutagenesis in murine zygotes
    de Bruin, Lisa Ott
    Yang, Wei
    Capuder, Kelly
    Lee, Yu Nee
    Antolini, Maddalena
    Meyers, Robin
    Gellert, Martin
    Musunuru, Kiran
    Manis, John
    Notarangelo, Luigi
    ONCOTARGET, 2016, 7 (11) : 12962 - 12974
  • [46] New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer
    Ahmed, Munazza
    Daoud, Grace Hope
    Mohamed, Asmaa
    Harati, Rania
    GENES, 2021, 12 (05)
  • [47] Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research
    Park, Cheol-Kyu
    Khalil, Maryam
    Pham, Nhu-An
    Wong, Stephanie
    Ly, Dalam
    Sacher, Adrian
    Tsao, Ming-Sound
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (03):
  • [48] Deep learning in cancer pathology: a new generation of clinical biomarkers
    Echle, Amelie
    Rindtorff, Niklas Timon
    Brinker, Titus Josef
    Luedde, Tom
    Pearson, Alexander Thomas
    Kather, Jakob Nikolas
    BRITISH JOURNAL OF CANCER, 2021, 124 (04) : 686 - 696
  • [49] Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer
    Zhang, Huimin
    Qin, Chunhong
    An, Changming
    Zheng, Xiwang
    Wen, Shuxin
    Chen, Wenjie
    Liu, Xianfang
    Lv, Zhenghua
    Yang, Pingchang
    Xu, Wei
    Gao, Wei
    Wu, Yongyan
    MOLECULAR CANCER, 2021, 20 (01)
  • [50] How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models
    van Gisbergen, M. W.
    Voets, A. M.
    Starmans, M. H. W.
    de Coo, I. F. M.
    Yadak, R.
    Hoffmann, R. F.
    Boutros, P. C.
    Smeets, H. J. M.
    Dubois, L.
    Lambin, P.
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2015, 764 : 16 - 30